As part of a person's first line of defense against viruses and other microbes that cause illness and disease, a whole network of proteins and other molecules detect and respond to intruders, which ...

The ability of protein kinases to transfer a phosphate group to target proteins plays an important role in many cellular ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention ...

Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.

Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A ...

Radiopharmaceutical biotech Actithera today announced the close of an oversubscribed $75.5 million Series A financing round.

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean Ventures ...

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

B7-33 is a synthetic peptide derived from the relaxin protein family, specifically designed to interact with the relaxin ...

Diets rich in phosphate additives, commonly found in processed foods, can increase blood pressure by triggering a brain ...